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Abstract To expand the available set of Baeyer–Villiger
monooxygenases (BVMOs), we have created expression
constructs for producing 22 Type I BVMOs that are present
in the genome of Rhodococcus jostii RHA1. Each BVMO
has been probed with a large panel of potential substrates.
Except for testing their substrate acceptance, also the enan-
tioselectivity of some selected BVMOs was studied. The
results provide insight into the biocatalytic potential of this
collection of BVMOs and expand the biocatalytic repertoire
known for BVMOs. This study also sheds light on the
catalytic capacity of this large set of BVMOs that is present
in this specific actinomycete. Furthermore, a comparative
sequence analysis revealed a new BVMO-typifying se-
quence motif. This motif represents a useful tool for effec-
tive future genome mining efforts.
Introduction
In the last few years, interest in using Baeyer–Villiger
monooxygenases (BVMOs) as biocatalysts has increased.
These flavin-dependent enzymes are able to perform effi-
cient chemo-, regio-, and/or enantioselective oxygenation
reactions using stoichiometric amounts of O2 as oxidant
and NAD(P)H as electron donor. It has been shown that
BVMOs can be used as biocatalysts for highly enantiose-
lective Baeyer–Villiger oxidations and sulfoxidations
(de Gonzalo et al. 2010). In addition, these oxidative bio-
catalysts have also been shown to catalyze oxygenation of
other heteroatoms like nitrogen, phosphor, selenium and
boron, as well as epoxidation reactions (Renz and Meunier
1999; Mihovilovic et al. 2004). Such selective oxygenation
reactions are difficult to perform selectively with chemical
catalysts rendering BVMOs a powerful tool in organic
chemistry.
Taking into account the urgent need for environmental
friendly processes, the use of biocatalysts is highly favour-
able due to the mild reaction conditions possible by employ-
ing enzymes such as BVMOs. However, there are still some
drawbacks concerning the applicability of these enzymes.
One of them is the fact that BVMOs are coenzyme depen-
dent and therefore need an NAD(P)H regeneration system.
Several different strategies have been applied to solve this
problem, like the use of whole cells or of a regeneration
enzyme partner (Hollmann et al. 2007; Torres Pazmiño et al.
2009). Another complicating factor is the limited availabil-
ity of suitable BVMOs. Of the several sequence-related
BVMOsubclasses,onlyBVMOsbelongingtotheTypeIclass
have been produced in a recombinant manner (Kamerbeek
et al. 2003; Torres Pazmiño et al. 2010). With the known Type
I BVMOs, only a limited set of reactions can be catalyzed.
Furthermore, some of these BVMOs that are of interest are
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Sulfoxidation.Enantioselectivityrather unstable. This is already evident from the most studied
BVMO: cyclohexanone monooxygenase (CHMO). This
BVMOfrom Acinetobacter has beenshowntoact ona variety
of compounds (Stewart 1998; Mihovilovic et al. 2002), but it
is very unstable (CHMO: t1/2024 h at 25 °C) (Zambianchi et
al.2002).Incontrast,phenylacetonemonooxygenase(PAMO)
from Thermobifida fusca is a very robust BVMO (t1/2024 h at
52°C) (Fraaijeet al. 2005; Secundo etal. 2011).Nevertheless,
its substrate scope is rather limited to small aromatic
substrates.
The above-mentioned current limitations in BVMO-
based biocatalysis has triggered enzyme discovery and en-
gineering studies to generate a larger collection of BVMOs
that show a good operational stability while covering a wide
variety of compounds. One approach to achieve this is to
engineer known BVMOs in order to create supplementing
activities and selectivities. For this purpose, several enzyme
engineering studies have been reported in recent years
(Torres Pazmiño et al. 2010). For example, PAMO has been
subjected to structure-based mutagenesis and this has
resulted in several mutants that display a somewhat altered
substrate range and/or enantioselectivity when compared
with the wild-type enzyme (Bocola et al. 2005;T o r r e s
Pazmiño et al. 2007;W ue ta l .2010; Dudek et al. 2011).
However, these enzyme engineering studies have also
shown that it is difficult to introduce substrate acceptance
profiles that are significantly different from the parent
enzyme.
To increase the number of available and distinct BVMOs,
also the natural diversity can be tapped. With the BVMO-
specific sequence motif it has become easy to survey se-
quenced genomes for BVMO-encoding genes (Fraaije
2002). Such identified genes can subsequently be cloned
and the corresponding proteins overexpressed for biocata-
lytic evaluation studies. Genome mining has already deliv-
ered a number of novel BVMOs (Torres Pazmiño et al.
2010). Even though BVMOs are widespread in bacteria
and fungi, the average distribution is only around one
BVMO-encoding gene per microbial genome (de Gonzalo
et al. 2010). In this respect, the bacterium Rhodococcus
jostii RHA1 is a peculiar and promising exception: its pre-
dicted proteome contains an unusually high variety in oxi-
dative enzymes, including >20 putative BVMOs (McLeod
et al. 2006). Szolkowy et al. (2009) already performed an
initial study on the BVMO repertoire of this organism and
identified several interesting activities but failed in express-
ing all BVMOs.
In this paper, we report on the exploration of 22 BVMOs
derived from R. jostii RHA1. By optimizing expression
vectors and expression conditions, all BVMOs were
obtained in a soluble form. Using a newly developed meth-
od to determine the amount of expressed and active BVMO
in a cell extract (CE) in combination with a novel generic
activity screening assay, the substrate profiles for a large set
of substrates for all 22 BVMOs have been determined.
Materials and methods
Reagents and enzymes
Oligonucleotide primers were purchased from Sigma,
dNTPs and In-Fusion™ 2.0 CF Dry-Down PCR Cloning
Kit from Clontech, Phusion polymerase from Finnzymes.
All other chemicals were obtained from Acros Organics,
ABCR, Sigma-Aldrich, TCI Europe, and Roche Diagnostics
GmbH.
Bacterial strains and plasmids
Escherichia coli TOP10 from Invitrogen was used as a host
for DNA manipulations and protein expression. Two expres-
sion vectors have been used: (1) a modified pBAD vector
(pBADN) in which the NdeI site was replaced by the orig-
inal NcoI site (Kamerbeek et al. 2004), and (2) the recently
engineered pCRE2 vector which harbors a codon-optimized
gene encoding a 18x mutant of phosphite dehydrogenase
(PTDH) with an N-terminal His-tag (Torres Pazmiño et al.
2009).
Sequence analysis, cloning and gene expression
The NCBI server was used for DNA sequence retrieval and
BLAST searches (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
The preliminary alignment of BVMOs was prepared using
ClustalW multiple alignment software (Thompson et al.
1994). Next, secondary structure information was extracted
from the recently elucidated PAMO structure containing
NADP
+ and a bound substrate analogue (PDB:2YLT, chain
A) (Orru et al. 2011) and used for adjustments of the
alignment. The alignments were also validated using GRDB
(Pasetal.2011).Forcalculationofthe Neighbor-Joiningtrees
and bootstrapping (1,500 iterations), we applied the MEGA5
software package (Tamura et al. 2011). The sequence-
homology derived branching diagrams were visualized by
using the iToL online tool (Letunic and Bork 2011).
Target genes were amplified using the genomic DNA of
R. jostii RHA1 (originally isolated by Seto et al. in 1995)a s
template. The genome of R. jostii RHA1 has been fully
sequenced (McLeod et al. 2006), and information can be
found at www.rhodococcus.ca. The genes were cloned into
pBAD or pCRE2 expression vectors using the In-Fusion
PCR Cloning kit from Clontech, following the recommen-
dations of the manufacturer. Gene #8 was cured by inserting
a nucleotide (C) at position 621. In this way, the stop codon
of the ORF RHA1_ro08999, encoding a putative N-terminal
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leucine. This amino acid was found most frequently in
BVMOs at the respective position. By the subsequent frame
shift ORF RHA1_ro08999 and RHA1_ro08998 are fused at
DNA level encoding a full length Type I BVMO. The inser-
tion was achieved by QuikChange® site-directed mutagenesis
using the following primers: forward, 5′-caccggtttcgggttcct
gaactcccccaa-3′, and reverse, 5′-ttgggggagttcaggaaccc
gaaaccggtg-3′.
Expression was tested using 24 deep square well micro-
titer plates in the sandwich cover system from Enzyscreen®,
shaking at 200 rpm. Cell cultures of 2.5 ml in Luria–Bertani
medium supplemented with 50 μgm l
−1 ampicillin were
grown at four different temperatures (17 °C for 48 h, 24 °C
for32h,30°Cand37°Cfor16h)withthreedifferentinducer
(arabinose) concentrations (0.002%, 0.02%, 0.2%, 0% as
control) each. CEs were obtained using DNase/lysozyme in
combination with freezing in liquid nitrogen and thawing at
30 °C. CEs as well as cleared cell extracts (CCEs) were
analyzed via SDS-PAGE for (soluble) expression of the
respective BVMOs.
BVMO concentration determination in cleared cell extract
Forthesubstratescreeningassays,cellculturesof500–800ml
Luria–Bertani medium supplemented with 50 μgm l
−1
ampicillin and the corresponding amount of arabinose
were grown. CE was prepared using sonication with subse-
quent centrifugation to remove the cell debris and obtain a
CCE.Anabsorptionspectrumofthe CCE was measuredfrom
700 to 300 nm (oxidized FAD), after which 500 μMN A D P H
was added. The sample was incubated at 25 °C for 10 min for
full flavin reduction, after which again a spectrum was mea-
sured. Subtracting the two collected spectra revealed the
amount of NADPH-reactive flavin in the CCE. To minimize
interfering absorbance due to protein aggregates of E. coli
proteins, the absorption at 440 nm was corrected by subtract-
ing the absorption value at 700 nm. The amount of flavin-
containing BVMO in the CCE was calculated using the dif-
ference extinctioncoefficientderivedfromPAMO:εdifference0
8.8 mM
−1 cm
−1.
Substrate screening
For activityscreening, an indirectactivityassay was used. The
substrates were dissolved in DMSO or dioxane. The solvent
(DMSO ordioxane)concentration was keptat5%inall tested
reactions. For the activity assay, 100 μl 50 mM Tris–HCl (pH
7.5), containing 1 or 5 mM substrate, 100 μM NADPH,
10 μM PTDH, 10 mM sodium phosphite and 1 μMB V M O
as CCE was incubated at 25 °C for 2 h. Twenty microliters of
the reaction mixture was subsequently mixed with 200 μl
molybdate reagent (10 mM (NH4)6Mo7O24 4H2O, 100 mM
Zn acetate, pH 5, adjusted with HCl) and 50 μl 10% ascorbic
acid (pH 5, adjusted with 40% NaOH). During incubation of
30 min at 30 °C a blue colored complex formed due to the
phosphate generated during the oxidation reaction (Saheki et
al. 1985). By measuring the absorption at 600 nm, the con-
centration of produced phosphate could be quantitatively de-
termined using a calibration curve. By being able to quantify
the amount of applied BVMO, each conversion could be
performed with a standard amount of BVMO which allows
a direct comparison.
GC analysis
For GC analysis, 500 μl incubations of 50 mM Tris–HCl
(pH 7.5), containing 5 mM substrate, 5% cosolvent (DMSO
or dioxane), 100 μMN A D P H ,3 . 1μM PTDH, 10 mM
phosphite and 5 μM BVMO (CCE) was incubated shaking
at 24 °C for 2 h. The reactions were then stopped by
extracting with ethyl acetate (2×0.5 ml, including 0.1%
mesitylene as an internal standard), dried with magnesium
sulfate and analyzed directly by GC to determine the degree
of conversion. For every tested reaction, control experi-
ments in the absence of enzyme resulted in no conversion.
Results
Identification of putative BVMO-encoding genes
By using protein sequences of PAMO and CHMO as baits for
BLASTP searches in the predicted proteome of R. jostii
RHA1 (McLeod et al. 2006), and inspecting individual puta-
tive BVMO sequences for known sequence motifs, 23 puta-
tive Type I BVMO genes could be identified (Table 1). For
consistency, we numbered the BVMOs according to the num-
bering employed in a previous study by the Grogan group
(Szolkowy et al. 2009). Compared with this study, our set of
BVMOs contains one more putative BVMO-encoding gene
thatwasnotidentifiedbefore(BVMO24).Furthermore,itwas
previously suggested that BVMO8 represented a BVMO
lacking a large part of the C-terminal domain which binds
the NADPH coenzyme (RHA1_ro08998). Careful inspection
of the sequenced genome revealed that a large part of a C-
terminal BVMO sequence (ORF RHA1_ro08999) resides
upstream of RHA1_ro08998 in the genome. Sequence analy-
sis revealed that only one nucleotide was missing to create a
gene encoding a full length BVMO, fusing both these open
reading frames. The corrected BVMO8 gene was generated
andincludedinthisstudy(seeMaterialsandmethods).Except
for these two newly reported BVMOs, BVMO8 and
BVMO24, we also discarded one gene from our study that
was previously assigned as a Type I BVMO (BVMO22 in
Szolkowy et al. 2009). Analysis of the respective protein
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monooxygenase (FMO), which is member of a flavoprotein
family that is distinct from BVMOs (Fraaije et al. 2002).
Furthermore, two BVMOs (BVMO21 and BVMO23) dif-
fered in only one amino acid out of 546 amino acids. Based
on sequence alignment with PAMOs, this residue (Leu or Arg
at position 480) is predicted to be on the surface of the protein
and therefore will have little effect on the catalytic properties
of these BVMOs. This has, in fact, been confirmed by the
previous study of the Grogan group (Szolkowy et al. 2009).
For this reason, BVMO23 was excluded from this study.
All identified BVMO sequences contained two con-
served Rossmann fold motifs: one near the N terminus and
one in the middle of the sequence (Table 1). In BVMO10
and BVMO18, the N-terminal GXGXXG motif is preceded
by ~120 amino acids instead of only ~20 amino acids.
This indicates that these enzymes have acquired an addi-
tional domain that is also found in a known BVMO, 4-
hydroxyacetophenone monooxygenase (HAPMO), and
which has been suggested to play a role in dimerization
(Kamerbeek et al. 2005). As described before, Type I
BVMOs contain a typifying short sequence motif:
FXGXXXHXXXW[P/D] (Fraaije et al. 2002). By allow-
ing one or two conservative mutations in this motif, all 22
sequences were found to contain such sequence motif. It
shows that not every residue of the previously described
motif is strictly conserved. While the glycine and tryptophan
residues are strictly conserved, some mutations (e.g., F>Yin
BVMO4), also occur which reflect the origin of the sequence
conservation within this motif. The BVMO motif is located
in a loop region of BVMOs that allows spatial rearrange-
ments during the catalytic cycle while it is not directly
involved in catalysis (Orru et al. 2011).
For illustrating the sequence relationships between the iden-
tified R. jostii sp. RHA1 BVMOs and some of the best charac-
terized BVMOs, all these sequences were aligned (see Fig. S1).
This revealed that the rhodococcal BVMOs are representatives
of many different clades of the Type I BVMO family. Careful
inspection of the structure-based multiple sequence alignment
also revealed another interesting conserved sequence motif.
Table 1 All identified BVMOs and their sequence characteristics from the predicted R. jostii RHA1 proteome
BVMO Accession number Rossman motif BVMO motif Rossman Motif Length (aa) Soluble expression
b Medium color
1 ro06679 GxGxxG FxGxxxHxxxWP GxGxxG 538 + B –
2 ro04304 GxGxxG FxGxxxHxxxWN GxGxxA 496 ++ C –
3 ro03247 GxGxxG FxGxxxHxxxWP GxGxxG 543 ++ C Blue
4 ro03063 GxGxxG YxGxxxHxxxWR GxGxxA 549 ++ B –
5 ro02109 GxGxxG FxGxxxHxxxWN GxGxxA 491 + C Blue
6 ro01874 GxGxxG FxGxxxHxxxWN GxGxxA 493 ++ B –
7 ro06008 GxGxxG FxGxxxHxxxWN GxGxxA 537 ++ C Blue
8
a ro08998/9 GxGxxG FxGxxxHxxxWD GxGxxA 545 ++ C –
9 ro09035 GxGxxG FxGxxxHxxxWP GxGxxG 541 ++ B –
10 ro09039 GxGxxG FxGxxxHxxxWD GxGxxS 663 ++ B –
11 ro06698 GxGxxG FxGxxxHxxxWP GxGxxG 545 ++ B –
12 ro07112 GxGxxG FxGxxxHxxxWD GxGxxA 514 ++ C Blue
13 ro03773 GxGxxG FxGxxxHxxxWP GxGxxA 515 + C –
14 ro03437 GxGxxG FxGxxxLxxxWP GxGxxG 547 ++ B –
15 ro02492 GxGxxG FxGxxxHxxxWP GxGxxG 553 ++ B –
16 ro02919 GxGxxG FxGxxxHxxxWP GxGxxG 498 ++ C –
17 ro05228 GxGxxG FxGxxxHxxxWD GxGxxA 603 + C Blue
18 ro05396 GxGxxG FxGxxxHxxxWP GxGxxS 652 ++ C –
19 ro05522 GxGxxG FxGxxxHxxxWN GxGxxA 515 + C Brown/blue
20 ro08137 GxGxxG FxGxxxHxxxWP GxGxxG 548 ++ B Brown/blue
21 ro10187 GxGxxG FxGxxxHxxxWP GxGxxG 546 ++ B Brown/blue
23 ro08185 GxGxxG FxGxxxHxxxWP GxGxxG 546 n.d n.d.
24 ro05323 GxGxxG FxGxxxSxxxWN GxGxxG 564 ++ B Yellow
n.d. not determined
aThis gene has been cured, see text
b++ indicates a clear visible protein band using SDS-PAGE; + indicates that no clear band was visible but flavin reduction was observed; B
indicates that the respective BVMO has been expressed using the pBADN vector; C indicates the use of the pCRE2 expression vector. The
underlined BVMOs were previously expressed in soluble form in a pET expression vector (Szolkowy et al. 2009)
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mentioned above, there is one particular region of the sequen-
ces that shows remarkable conservation, located between the
N-terminal GxGxxG motif and the known BVMO motif. This
region can be defined by [A/G]GxWxxxx[F/Y]P[G/M]xxxD.
The full conservation of the aspartate is in full agreement with
the recent finding that Asp66 in PAMO plays a crucial role in
catalysis by direct interaction with the NADP
+ coenzyme.
Mutating this residue into an alanine resulted in inactivation
of the enzyme by decreasing the rate of NADPH-mediated
flavin reduction (Orru et al. 2011). Combined with Arg337
(in PAMO), these two residues represent the only fully con-
served active site residues, both crucial for catalysis. The con-
served doublet of glycine residues in this newly recognized
motif is a known motif for a Rossmann fold domain and in the
BVMOs they support effective binding of the FAD cofactor.
The other conserved residues in the motif center around the
flavin cofactor and appear to be essential for creating a produc-
tiveactivesitearchitecture(seeFig.S2).Thisnewlyrecognized
motif appears to be more discriminative for identifying BVMO
sequences as it entails more and more conserved residues. It
also clearly differentiates between BVMO and FMO sequences
as the structure and sequence region around Asp66 (in PAMO)
in FMOs is totally different (Fraaije et al. 2002; Alfieri et al.
2008). Therefore, this motif represents a new and more reliable
tool to annotate putative BVMO-encoding genes.
In order to obtain a better view on the sequence–function
relationship among the tested set of BVMOs, another se-
quence alignment was also performed. Using the recently
elucidated crystal structure of PAMO, which contains
NADP
+ and a substrate analogue (MES), we identified all
residues that are within a 12-Å radius from the sulfur atom
of the substrate analogue (Orru et al. 2011). This yielded a
set of 59 residues that form the core of the substrate binding
pocket and that are spread over the PAMO sequence. Upon
performing a structure-based multiple sequence alignment,
we filtered for all respective 59 residues for generating a
separate multiple sequence alignment. We anticipated that
such an approach of comparing partial sequences would
have a higher probability to disclose similarities in substrate
specificities. In Fig. 1, the branching diagram representation
of this focussed sequence alignment of all tested and known
Fig. 1 Radial branching
diagram of the comparison of
active site residues of the
selected BVMO protein
sequences. The included
sequences are: AlmA1,
Acinetobacter sp. DSM 17874
(ABQ18224.1); EtaA,
Mycobacterium tuberculosis
H37Rv (NP_218371.1);
HAPMO, Pseudomonas
fluorescens ACB (Q93TJ5.1);
MoxY, Aspergillus flavus
(AAS90037.1); PtlE,
Streptomyces avermitilis MA-
4680 (NP_824170.1); CDMO,
Rhodococcus ruber SCI
(AAL14233.1); CPDMO,
Pseudomonas sp. strain HI-70
(BAE93346.1); CHMO, Acine-
tobacter calcoaceticus NCIMB
9871 (BAA86293.1); PAMO, T.
fusca (YP_289549.1); STMO,
Rhodococcus rhodochrous
(BAA24454.1); ACMO, Gor-
dania sp. strain TY-5
(BAF43791.1); MEKMO,
Pseudomonas veronii MEK700
(ABI15711.1); CPMO, Coma-
monas sp. strain NCIMB 9872
(Q8GAW0)
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global multiple sequence alignment and was used for the
discussion below.
Expression of the putative BVMOs
All 22 putative BVMO-encoding genes were cloned into a
slightly modified pBAD expression vector (Kamerbeek et
al. 2004) using a ligation free cloning method. Subsequent-
ly, expression tests were performed in which the temperature
and arabinose concentration was varied. With these con-
structs, 11 BVMOs could be obtained in soluble form with
goodexpression levels, using E. coliTOP10 as host(Table 1).
A similar success ratewas previouslyobtainedfor roughly the
samesetofgenesusingapET-basedE.coliexpressionsystem
(Szolkowy et al. 2009) (see Table 1). In the other cases, the
expressedprotein waseitherinsoluble orthe expressionlevels
of soluble protein were very low. To increase the expression
level and/or solubility, the 11 BVMO genes that could not be
expressed using pBAD were cloned into the recently devel-
oped pCRE2 expression vector and tested using various ex-
pressionconditions(TorresPazmiñoetal.2009).Thisresulted
in good expression levels of soluble protein of most of these
genes. Only in five cases was poor soluble protein expression
observed. Nonetheless, by using the NADPH-dependent fla-
vin reduction method (vide infra) it was found that also these
constructs led to expression of detectable levels of soluble
NADPH-reactive proteins. Taken together, by using two ex-
pression vectors and careful tuning of expression conditions,
we succeeded in producing all 22 targeted BVMOs in a
soluble form.
Interestingly, for a number of constructs it was found
that, using the optimal expression conditions, the growth
medium changed significantly in color (Table 1). Such a
phenomenon had been observed before in a BVMO muta-
genesis study where the M446G PAMO mutant was created
(Torres Pazmiño et al. 2007). This mutant BVMO was
found to form indigo blue by oxidizing indole which is
present in the cytosol of E. coli. Also for some of the
expressed rhodococcal BVMOs a blue color was observed
while some other constructs led to a more brownish or
intense yellow color. Apparently, some of the expressed
BVMOs act on endogenous compounds present in the cul-
ture medium or in the cells which confirms functional ex-
pression of these monooxygenases.
Substrate profiling
To establish the biocatalytic potential of this large set of
BVMOs, we aimed at testing each of these BVMOs for
activity on a large panel of potential substrates. For such
substrate profiling study, we first set out to quantify the
amount of active enzyme in CCEs. Based on the fact that
all Type I BVMOs contain a FAD cofactor that is specifi-
cally reduced by NADPH, we developed a simple method
for accurate BVMO concentration determination. This ap-
proach is somewhat analogous to the well-known method to
quantify the amount of P450 monooxygenases by using the
specific heme absorption features of reduced P450 mono-
oxygenases with carbon monooxide. In E. coli only a mi-
nority of the native proteins contains a flavin cofactor and
most of them will not be reactive with NADPH. In contrast,
the overexpressed BVMOs will be dominant in the respec-
tive extracts, outnumbering the endogenous flavoproteins of
E. coli. By measuring the absorbance spectrum of the CCE
before and after the addition of NADPH the amount of
NADPH-reactive flavin cofactor in the expressed BVMO
can be determined (Fig. 2). Therefore an extinction coeffi-
cient is needed which reflects the absorbance difference
between an oxidized and reduced BVMO. For this, we used
the extinction coefficients for oxidized PAMO (ε441 nm ox0
12.3 mM
−1 cm
−1) and reduced PAMO (ε441 nm red0
3.6 mM
−1 cm
−1) to calculate an estimate of the difference
extinction coefficient for FAD containing BVMOs at
440 nm (ε440 nm, BVMO08.8 mM
−1 cm
−1). We decided to
use the absorption at 440 nm and to neglect the small differ-
ences caused by different flavin microenvironments in indi-
vidual BVMOs. This corroborates with flavin absorbance
spectral data of known BVMOs from literature which dis-
play highly similar absorbance maxima and extinction coef-
ficients (Table 2). Validation of the method by using purified
enzyme with a known concentration showed that the method
is accurate. Furthermore, using extracts of E. coli devoid of
any expressed BVMO did not show any significant A440
change after incubation with NADPH, indicating that there
is no interfering absorbance. Using this method, it was
possible to determine the concentration of soluble BVMO
in all 22 samples, independent of the level of BVMO over-
expression. In this way, we could normalize the amount of
Fig. 2 Absorbance spectra of a cleared cell extract containing overex-
pressed BVMO. The spectra of the oxidised flavin cofactor in
BVMO14 (continuous line) and after reduction by NADPH (broken
line) are shown. The difference in absorbance at 440 nm that can be
used to determine the BVMO concentration is indicated
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while using CCEs.
For substrate profiling we used 39 substrates, represent-
ing different compound classes: linear aliphatic ketones,
cyclic aliphatic ketones, aromatic ketones, aromatic amines,
and aromatic sulfides (Table 3). All substrates were used at
two different concentrations (5 and 1 mM) and a fixed
amount of cosolvent was used. For determining activity
for each tested compound, we initially used the NADPH
depletion assay. Consumption of NADPH by BVMO can be
monitored by measuring the absorbance of NADPH at
340 nm. However, this assay could not be used for com-
pounds that absorbed in the same wavelength regime of
NADPH (300–390 nm) and only allowed to measure the
conversion of relatively small concentrations of NADPH
and substrate. Therefore, we decided to use an assay that
is coupled to the activity of the employed regeneration
enzyme which allows us to monitor conversion over a
longer time period. For this, PTDH was used which gener-
ates one molecule of phosphate for the regeneration of each
NADPH molecule. The formed phosphate could be quanti-
fied by using a chromogenic reaction allowing spectropho-
tometric detection of the degree of conversion. The
conversions were incubated for 2 h before measuring the
phosphate concentrations. As BVMOs can also act as
NADPH oxidases in the absence of a suitable substrate,
formation of phosphate was only regarded as significant
when it was significantly more when compared with the
incubation without a test compound. By this, poor substrates
will be overlooked while establishing profiles of efficient
substrates for all tested BVMOs.
The observed substrate profiles for all tested BVMOs are
summarized in Table 3. The results disclose a broad sub-
strate scope for the produced set of 22 BVMOs. To verify
the results, we checked a selection of substrates for conver-
sion with several BVMOs by GC analysis which confirmed
the majority of the identified substrates. For the majority of
the tested compounds, we could find at least one active
enzyme, even though the intensity of the activity varies a
lot between the tested BVMOs. Nonetheless, for eight
BVMO (BVMOs 1, 3, 6, 7, 8, 13, 16, and 17) no significant
activity was observed for any of the tested compounds.
However, it is worth noting that of these BVMOs, BVMO3,
BVMO7, and BVMO17 appear to produce some indigo
blue when expressed in E. coli (Table 1). This suggests that
these BVMOs are indeed active while not very efficient on
any of the compounds in our test panel. Another relevant
observation is the fact that conversions using BVMO3,
BVMO8, BVMO13 and BVMO19 in the absence of sub-
strate results in a 4- to 5-fold higher background reaction
when compared with all other tested BVMOs (~9 mM phos-
phate formed instead of ~2 mM). For BVMO13 and
BVMO19 this can be explained by the fact that their ex-
pression was poor which dictated the use of relatively high
amounts of extract which leads to a relatively high back-
ground NADPH consumption. Contrarily, BVMO3 and
BVMO8 are well expressed. This suggests that these
BVMOs display an exceptionally high uncoupling rate and
therefore substrates may be unnoticed by monitoring
NADPH consumption or phosphate formation. It also agrees
with the fact that Szolkowy et al. (2009) have found that
BVMO3 is indeed active on a number of ketones. For the
BVMOs that did not display significant background
NADPH consumption or uncoupling rates, the substrate
acceptance profiles varied considerably. Among the tested
BVMOs, only a small set of five BVMOs were shown to be
active on ≥10 tested compounds, leaving only five potent
BVMOs. This contrasts the catalytic potential of well char-
acterized BVMOs that were also tested with the panel of test
compounds (Table 3). As known from the literature,
CHMO, CPMO, PAMO and HAPMO were indeed found
to accept a broad range of compounds. Only STMO, for
which a substrate profile had not yet been established,
appeared rather selective by converting only nine of the
tested compounds. Similar to the known prototype BVMOs,
two rhodococcal BVMOs, BVMO4 and BVMO24,
appeared to be very substrate tolerant as they both accepted
the majority of the tested compounds. Their substrate pro-
files resemble, to a large extent, that of CPMO, with
BVMO24 exhibiting greater efficiency when compared with
BVMO4. It is worth noting that BVMO24 had escaped the
previous rhodococcal BVMO exploration study by the
Table 2 Collection of literature and measured values for λmax and εox of known BVMOs
PAMO
(Fraaije et al. 2005)
HAPMO
(Kamerbeek et al. 2001)
CHMO
(Sheng et al. 2001)
STMO
(Miyamoto et al. 1995)
CPMO
a CPDMO
a
Buffer 50 mM Tris/Cl,
pH 7.5
50 mM phosphate,
pH 7.0
50 mM phosphate,
pH 7.2
100 mM phosphate
pH 7.4
50 mM Tris/Cl
pH 7.5
50 mM Tris/Cl
pH 7.5
lmax (nm) 441 439 440 439 444 442
εox (mM
−1 cm
−1) 12.3 12.4 13.8 n.r. 14.5 12.8
n.r. no extinction coefficient has been reported
aThese BVMOs were purified as PTDH fusion enzymes and analysed spectrophotometrically (this study)
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also were found to be active on a number of cycloalkanones.
BVMO9 and BVMO15 showed high activity with a number
of aromatic ketones, resembling to some extend the substrate
Table 3 Substrate profiling
2 4 5 9 10 11 12 14 15 18 19 20 21 24 PA CP CH ST HAP
1 Acetone
a ++ + + + +
2 2-Butanone + ++ + +
3 2-Octanone + + + + + ++ ++ + +++
4 2-Dodecanone ++ + + +++ +++ +++
5 3-Octanone + ++ ++ +++
6 4-Octanone + + + ++ ++ + +
7 Methylvinylketone + + + + + ++ + ++ + +++
8 3-Methyl-2,4-pentanedione + + + + ++ ++ +++
9 Cyclobutanone + + + ++ ++ +++
10 Cyclopentanone + + + + ++ ++ ++ +
11 Cyclohexanone + + + ++ +++ ++ +
12 Cyclopentadecanone + ++ + +
13 Oxocyclohexanecarbonitrile + + ++ ++ +++
14 4-Methylcyclohexanone + +++ ++ +
15 2-Propylcyclohexanone + + + +++ ++ + +
16 Dihydrocarvone + + + ++ ++ +++
17 Cyclopropylmethylketone + + + + ++ +++
18 Norcamphor + + + ++ +++ ++ +
19 Bicycloheptenone +++ + + + ++ +++ ++ +++
20 Thioanisole + + ++ ++ +++
21 Benzylethyl sulfide + + + ++ ++ ++ +++
22 Benzylphenyl sulfide + + ++ ++ + +++
23 Ethionamide + ++ + ++ +++ + +++ +++
24 Modafinil precursor + + +++ +
25 Thiacetazone + + ++ + + +
26 Nicotin + + ++ +
27 Indole ++
28 3-Acetylindole ++ + + + +++
29 Acetophenone + + ++ ++ +++ +++
30 4-Hydroxyacetophenone + + + +++ + + ++ +++
31 2,6-Dihydroacetophenone + + ++ +++
32 3-Phenylpentane-2,4-dione + + +++ ++ + +
33 Phenylacetone + + +++ + + +++ ++ + +++
34 Raspberry ketone + ++ + + + +++ + + +++
35 2-Phenylcyclohexanone + + ++ ++
36 Benzoin + +++
37 Phenendione +++ + +
38 2-Indanone + + ++ +++ +
39 1-Indanone + + ++ +
Total substrates 6 29 3 6 5 1 1 2 10 3 1 14 11 25 12 38 19 9 33
Activities as measured by phosphate formation are indicated for the rhodococcal BVMOs and prototype BVMOs. BVMOs that did not show any
activity on the tested compounds were excluded. The rhodococcal BVMOs are indicated by their respective numbers. The observed activities are
indicated as +, ++ or +++ and reflect 1.2-, 2- or 5-fold the phosphate formation (cq. conversion), respectively, when compared with incubations
lacking the tested compound
PA PAMO, CP CPMO, CH CHMO, ST STMO, HAP HAPMO
aFor the structural formulas and other details, see Supplementary information
1486 Appl Microbiol Biotechnol (2012) 95:1479–1489scope of HAPMO. Other BVMOs appeared to be rather
restricted in substrate scope. For example, BVMO10 appears
to be very selective in acting on bulky ketones converting
bicycloheptenone and phenendione. Still, these BVMOs may
be valuable biocatalysts exhibiting new substrate specificities
and chemo-, regio-, or enantioselectivities.
To have a better insight into the biocatalytic potential of
some of the BVMOs, a selected set was studied for the
conversion of some typical BVMO substrates, including
prochiral sulfides. Table 4 shows that all these BVMOs
convert the typical BVMO substrates phenylacetone and
bicycloheptenone. BVMO8 gives poor conversion of phe-
nylacetone while none of the other compounds are con-
verted. This confirms the outcome of the activity screening
which did not reveal any substrate for this enzyme. The fact
that for phenylacetone conversion is observed is due to the
fact that the conversions have been performed over a rela-
tively long time period. For 2-indanone, only BVMO24 was
found to be reactive which is also in line with the substrate
profiling study (Table 3). Except for BVMO15, BVMO20
and BVMO8, the two aromatic sulfides were efficiently
converted with good to excellent enantioselectivities. Strik-
ingly, most of the BVMOs show the same enantioselectivity
forming predominantly one specific sulfoxide enantiomer of
each of the two aromatic sulfides. Only BVMO24 is again
an exception and shows opposite enantioselectivity.
Discussion
By employing two expression vectors and screening for
proper expression conditions, we have been able to express
22 Type I BVMOs from R. jostii RHA1. This is the largest
set of recombinant BVMOs produced from one microbial
origin reported so far. The collection supplements the pre-
vious set of 13 BVMOs produced by the Grogan group.
Except for establishing the expression conditions for
BVMOs that could not be expressed before, we also identi-
fied two new BVMO genes (BVMO8 and BVMO24). The
biocatalytic exploration of this new collection of BVMOs
was aided by the development of two new methods: (1) by
exploiting the distinct absorbance features of oxidized and
reduced protein-bound FAD, the BVMO content in the
extract could be determined; and (2) by performing the
conversions coupled to NADPH regeneration by PTDH,
conversion could be quantified by colorimetric phosphate
detection. Sequence analysis also revealed a novel BVMO-
typifying motif: [A/G]GxWxxxx[F/Y]P[G/M]xxxD. This
motif includes residues that are part of the active site and
therefore represents a useful tool for annotating BVMO-
encoding genes. The motif is absent in FMO sequences and,
therefore, allows discrimination between members of the two
sequence-relatedflavoproteinsubfamilies,BVMOsandFMOs.
The unraveled substrate profiles of the studied BVMOs
differed significantly among the produced BVMOs. For
some BVMOs no substrate could be identified by using a
test set of 39 compounds. This could indicate that the natural
substrates for these enzymes differ too much from the tested
compounds. However, it may also be that these BVMOs
only display very low oxygenation activities that could not
be detected with the employed assay. Such low activity has
also been observed for EtaA from Mycobacterium tubercu-
losis (Fraaije et al. 2004). This drug-resistance related en-
zyme was shown to act on a variety of typical BVMO
substrates but with very low activity. A small number of
the produced BVMOs were active on ≥10 compounds:
BVMO4, BVMO15, BVMO20, BVMO21, BVMO24.
BVMO24 appeared to be a very potent biocatalyst as it
showed very good activities on 26 compounds. BVMO3
may also belong to this group of potent BVMOs but appears
to act as NADPH oxidase, which prevented establishing its
true substrate profile. To correlate sequence to substrate
profiles, we generated a branching diagram that is based
on the comparison of residues that make up the core of the
active site. This revealed that all BVMOs that displayed a
relaxed substrate acceptance profile were closely related to
the clades that include the well known prototype BVMOs
(CHMO, CPMO, PAMO and STMO). The above mentioned
potent rhodococcal BVMOs, including BVMO3, are all
closely related to these prototype BVMOs (Fig. 1).The
Table 4 GC analyses of sub-
strate conversions by selected
BVMOs
The conversions are indicated as
percentage (%). Enantioselectiv-
ities are indicated as enantiomeric
excess(%).Forsomeincubations,
the enantioselectivity has not
been determined (n.d.)
Substrate BVMO
3 8 9 1 41 52 0 2 12 4
Phenylacetone 99 27 99 99 92 45 99 38
2-Indanone <3 <3 <3 <3 <3 <3 <3 62
Bicycloheptenone 97 <3 36 97 90 97 97 93
Thioanisole 87 <3 21 99 76 24 55 80
Enantioselectivity 90 (S) n.d. 61 (S) n.d. 45 (S) 5 (S) 63 (S) 82 (R)
Benzylethyl sulfide 60 <3 <3 72 14 4 92 91
Enantioselectivity 75 (R) n.d. n.d. 90 (R) 20 (R) n.d. 93 (R) >99 (S)
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groups that include other known but less explored BVMOs
(HAPMO, MoxY, EtaA, AlmA) appear to be less promising
biocatalysts. This observation is valuable for future BVMO
discovery efforts: it appears more productive to search for
homologs of the typical prototype BVMOs when looking
for potent biocatalysts.
Two BVMOs display a peculiar behavior: BVMO3 and
BVMO8 act as NADPH oxidases when no potential sub-
strate is present. For the other BVMOs and all previously
characterized Type I BVMOs, this futile oxidation of
NADPH was typically very slow. The relatively high
NADPH oxidase activity may reflect the fact that these
respective BVMOs do not function properly when taken
out of their natural context. Alternatively, it may indicate
that these enzymes have acquired NADPH oxidase activity
for a certain purpose, e.g., to regenerate NADP
+ in the cell
or to produce H2O2. Production of H2O2 complies with the
recent discovery that actinomycetes are relatively rich in
peroxidases (van Bloois et al. 2010). In line with this, a
DyP-type lignin peroxidase from R. jostii sp. RHA1 has
recently been identified and characterized (Ahmad et al.
2011). Except for displaying NADPH oxidase activity,
BVMO3 also was found to be acting as an oxygenase as
the cells expressing this enzyme developed a blue color
indicative of indole oxygenation. This would imply that
BVMO3 and BVMO8 have a dual function in R. jostii
RHA1: acting as oxygenases or NADPH oxidases. In this
context, it is worth noting that, due to a missing nucleotide,
the gene encoding BVMO8 is disrupted. This may reflect
that due to the relative high NADPH oxidase activity, gen-
erating toxic hydrogen peroxide, it was beneficial to silence
the gene. Further work on the enzymes reported in this study
will disclose details on their catalytic properties and bioca-
talytic potential.
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